中國中藥(00570.HK)2021年純利升16.2%至19.33億元 中藥配方顆粒產品銷售顯著增長
格隆匯3月26日丨中國中藥(00570.HK)公佈2021年度業績，集團實現營業額190.53億元人民幣(單位下同)，同比增長28.7%；毛利118.29億元，同比增長29.6%；公司擁有人應占溢利19.33億元，同比增長16.2%；每股基本盈利38.38分，宣派末期股息每股5.98分，連同中期股息每股5.54分，全年合共派息每股11.52分。
公吿稱，營業額增長主要得益於中藥配方顆粒的質量可控性及便利性等優勢明顯，以及卓有成效的學術推廣，市場認可度繼續提高，推動業務穩步發展；隨着疫情好轉，成藥業務逐步恢復，重點臨牀品規銷售額保持增長；中藥飲片、中藥大健康產品、國醫館綜合服務開拓新業務，助力增長；中藥材綜合業務加大推進基地建設，積極探索和拓展道地中藥材經營業務，對外經營發展迅速。
按照各業態產品營業額分析，中藥材綜合業務營業額約7.53億元，佔總營業額的4.0%；中藥配方顆粒產品營業額約134.00億元，佔總營業額的70.3%；中藥飲片產品營業額約14.67億元，佔總營業額的7.7%；成藥產品營業額約31.94億元，佔總營業額的16.7%；中藥大健康產品營業額約9351.50萬元，佔總營業額的0.5%；國醫館綜合服務營業額約1.45億元，佔總營業額的0.8%。
2021年，集團緊緊圍繞”全面建設可持續、互協同、共發展的中藥大健康全產業鏈，打造行業領先水平的中藥大健康產業集團“的發展目標，結合中藥行業整體及公司業務涉及的各細分領域情況，制定並全面推進”十四五“戰略規劃，不斷強化戰略執行能力，持續穩固工業製造優勢，加大科研創新投入力度，積極優化各板塊協同，進一步提升資源整合能力，向着中藥行業引領者的目標更進一步。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
